hers glp-1 Hims & swings to a loss in Q1 amid shift in strategy hers glp 1 injection Hims

Asia-Pacific is expected to be the fastest growing region in the GLP-1 receptor agonists obesity drugs market during the forecast period due to increasing obesity rates, rising healthcare awareness, and expanding access to advanced diabetes and obesity care Long-acting GLP-1 Receptor Agonists segment dominated the GLP-1 receptor agonists obesity drugs market with a market share of 55.5% in 2024, driven by its superior weight loss efficacy, once-weekly dosing convenience, and broad adoption of drugs such as semaglutide and tirzepatide Report Scope and GLP-1 Receptor Agonists Obesity Drugs Market Segmentation GLP-1 Receptor Agonists Obesity Drugs Market Trends Expansion Beyond Diabetes Through Multi-Indication Approvals A significant and accelerating trend in the global GLP-1 receptor agonists obesity drugs market is the expansion of these therapies beyond type 2 diabetes into broader indications such as chronic obesity, cardiovascular risk reduction, and potentially even conditions such as sleep apnea and nonalcoholic steatohepatitis (NASH)

While it may be tempting to increase alertness with coffee when feeling low on energy, immoderate consumption has the opposite effect

The research also highlights that the maintenance phase of creatine is sufficient to: Maintain elevated muscle creatine stores in the body

Skin also receives internal defense against damage and inflammation

Local autocrine plasticity signaling in single dendritic spines by insulin-like growth factors